许德凤, 高和, 笪冀平, 刘锦铭, 张开泰, 张波. 肺癌中p16及pRB与cyclinD1和PCNA基因蛋白的表达及预后意义的评估[J]. 中国肿瘤临床, 2004, 31(19): 1094-1097.
引用本文: 许德凤, 高和, 笪冀平, 刘锦铭, 张开泰, 张波. 肺癌中p16及pRB与cyclinD1和PCNA基因蛋白的表达及预后意义的评估[J]. 中国肿瘤临床, 2004, 31(19): 1094-1097.
Xu Defeng, Gao He, Da Jiping, Liu Jinming, Zhang Kaitai, Zhang Bo. Nm A Study of their Relationship with Prognosis and Protein Expression of P16,Rb,cylinDI and PCNA in Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 31(19): 1094-1097.
Citation: Xu Defeng, Gao He, Da Jiping, Liu Jinming, Zhang Kaitai, Zhang Bo. Nm A Study of their Relationship with Prognosis and Protein Expression of P16,Rb,cylinDI and PCNA in Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 31(19): 1094-1097.

肺癌中p16及pRB与cyclinD1和PCNA基因蛋白的表达及预后意义的评估

Nm A Study of their Relationship with Prognosis and Protein Expression of P16,Rb,cylinDI and PCNA in Lung Cancer

  • 摘要: 目的 :研究抑癌基因蛋白p16、pRB、细胞周期素D1(cyclinD1)及PCNA在肺癌中的表达及与预后的关系。 方法 :应用免疫组织化学方法检测p16、pRB、cyclinD1及PCNA的表达,结果由COX回归模型与Kaplan-Meier单因素分析处理。 结果 :1)65例肺癌标本均示PCNA阳性,但表达程度不同,非小细胞肺癌(NSCLC)>小细胞肺癌(SCLC),P<0.05。PCNA高表达与p16-、pRB+、PT状况、远处转移呈正相关。增殖指数(PI)Ⅰ-Ⅱ级的生存时间≥24个月为81.82%,Ⅲ-Ⅳ级为18.18%,P<0.01。2)p16阳性率为50.77%,p16的表达与腺癌分化程度有关,高分化>中分化>低分化,P<0.01,与鳞癌分化无关。p16+与p16-患者生存期≥24个月的比率分别为72.73%和27.27%,P<0.05。pRB阳性表达率为58.46%,鳞癌、腺癌较高,SCLC较低,与生存期无关。cyclinD1阳性表达率为60.00%,其中鳞癌72.41%,腺癌58.33%,SCLC 25.00%,P=0.05。3)p16-/pRB+细胞增殖活性较强,生存期较短;cyclinD1+/p16-/pRB+生存期较短,增殖活性较强。 结论 :PCNA及p16分别是肺癌进展及预后判断的独立指标;PCNA、p16、pRB、cyclinD1联合检测对肺癌的预后评估更有价值和更客观;小细胞肺癌pRB表达的缺失具有鉴别诊断意义。

     

    Abstract: Objective :To investigate the relationshp of survival time and expression of pl6,Rb,cylinDI and PCNA in lung cancer. Methods :Immunohistochemical techniques were applied to study the expression of PCNA,p16,pRB,cydinDI.The results were analyzed by Cox-Model and single factor Kaplan-Meier assay., Results :1.the PCNA protein was expressed in all lung specimens (65 specimens ) with different level.The expression of NSCLC were stronger than that of SCLC (P<0.05).The high expression of PCNA was correlated with p16 negative, pRB positive,ptumor status and distant metastasis.The high PI was correlated with poor prognosis (survival time≥24 months) being 81.82 percent for PI (PCNA index)I-II and 18.18 percent for PI III-VI respectively,p<0.01.2.The positive rate of p16 (50.77%) was correlated with differentiation degree of adenocarcinoma,the higher differentiation, the higher positive rate (P<0.01).But as far as squamous cell carcinomas was concerned,it had no relationship with differentiation. The survival time ≥24 months of patients with p16 negative and p16 positive was 72.73% and 27.27%, respectively(P<0.05). The positive rate of pRB (58.46%) in NSCLC were significantly more than that of SCLC.The positive rate of cylinDI was 60%, squamous cell carcinomas 72.41%,adenocarcinoma 58.33 percent,SCLC 25.00 percent respectively.A statistical significant difference existed among the three kinds of lung cancer. 3 Cases with p16-pRB+ had a higher cell proliferation activity and shorter survival time. So did for cases with cylinDI+ p16-pRB+. Conclusions :PCNA and p16 were independent markers for progress of lung cancer.When PCNA 、p16、pRB and cyclinDI were detected together.This was the most relevant conbination of alterations contributing to prognosis.Lose of pRB expression in SCLC suggest that it is different from NSCLC diognostidy.

     

/

返回文章
返回